Seeking Alpha

More on Transcept Pharmaceuticals (TSPT): Q3 easily beats estimates across the board. Revenue...

More on Transcept Pharmaceuticals (TSPT): Q3 easily beats estimates across the board. Revenue topped consensus expectations, boosted in part by a $10M milestone payment from Purdue Pharmaceutical for the listing of a TSPT method of use patent in the FDA's Orange Book, while better EPS performance was driven by lower R&D expenses. Shares +3.5% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)